Invokamet XR

Invokamet XR · pharmadog

Patent cliff

source: FDA Orange Book

first barrier falls

Jul 14, 2027

~1.0 years out

Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.

patents (52)

Jul 6, 2030formulationUS 115768944.0y
Jul 6, 2030formulationUS 115768944.0y
Jul 6, 2030formulationUS 115768944.0y
Jul 6, 2030formulationUS 115768944.0y
Aug 26, 2029patentUS 7943582*PED3.1y
Aug 26, 2029patentUS 7943582*PED3.1y
Aug 26, 2029patentUS 7943582*PED3.1y
Aug 26, 2029patentUS 7943582*PED3.1y
Aug 26, 2029patentUS 7943582*PED3.1y
Aug 26, 2029patentUS 7943582*PED3.1y
Aug 26, 2029patentUS 7943582*PED3.1y
Aug 26, 2029patentUS 7943582*PED3.1y
Feb 26, 2029compositionUS 79435822.6y
Feb 26, 2029compositionUS 79435822.6y
Feb 26, 2029compositionUS 79435822.6y
Feb 26, 2029compositionUS 79435822.6y
Feb 26, 2029compositionUS 79435822.6y
Feb 26, 2029compositionUS 79435822.6y
Feb 26, 2029compositionUS 79435822.6y
Feb 26, 2029compositionUS 79435822.6y
Jun 3, 2028patentUS 8513202*PED1.9y
Jun 3, 2028patentUS 8513202*PED1.9y
Jun 3, 2028patentUS 8513202*PED1.9y
Jun 3, 2028patentUS 8513202*PED1.9y
Jun 3, 2028patentUS 8513202*PED1.9y
Jun 3, 2028patentUS 8513202*PED1.9y
Jun 3, 2028patentUS 8513202*PED1.9y
Jun 3, 2028patentUS 8513202*PED1.9y
Jan 14, 2028patentUS 7943788*PED1.5y
Jan 14, 2028patentUS 7943788*PED1.5y
Jan 14, 2028patentUS 7943788*PED1.5y
Jan 14, 2028patentUS 7943788*PED1.5y
Jan 14, 2028patentUS 7943788*PED1.5y
Jan 14, 2028patentUS 7943788*PED1.5y
Jan 14, 2028patentUS 7943788*PED1.5y
Jan 14, 2028patentUS 7943788*PED1.5y
Dec 3, 2027compositionUS 85132021.4y
Dec 3, 2027compositionUS 85132021.4y
Dec 3, 2027compositionUS 85132021.4y
Dec 3, 2027compositionUS 85132021.4y
Dec 3, 2027compositionUS 85132021.4y
Dec 3, 2027compositionUS 85132021.4y
Dec 3, 2027compositionUS 85132021.4y
Dec 3, 2027compositionUS 85132021.4y
Jul 14, 2027compositionUS 79437881.0y
Jul 14, 2027compositionUS 79437881.0y
Jul 14, 2027compositionUS 79437881.0y
Jul 14, 2027compositionUS 79437881.0y
Jul 14, 2027compositionUS 79437881.0y
Jul 14, 2027compositionUS 79437881.0y
Jul 14, 2027compositionUS 79437881.0y
Jul 14, 2027compositionUS 79437881.0y

FDA exclusivities (16)

Jun 18, 2028PEDPediatric (6mo bonus)2.0y
Jun 18, 2028PEDPediatric (6mo bonus)2.0y
Jun 18, 2028PEDPediatric (6mo bonus)2.0y
Jun 18, 2028PEDPediatric (6mo bonus)2.0y
Jun 18, 2028PEDPediatric (6mo bonus)2.0y
Jun 18, 2028PEDPediatric (6mo bonus)2.0y

(canagliflozin + metformin hydrochloride ER)

indications

all catalysts(0)

News(0)

Patent cliff

patents (52)

FDA exclusivities (16)

comments(0)

Report a data issue